Tags

Type your tag names separated by a space and hit enter

[Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations].
Fortschr Neurol Psychiatr 2007; 75(9):515-27FN

Abstract

Elevated concentration of total homocysteine (Hcy) in plasma (> 12 micromol/l) is a risk factor for several diseases of the central nervous system. Epidemiological studies have shown a dose-dependent relationship between concentrations of Hcy and the risk for neurodegenerative diseases. Hcy is a marker for B-vitamin deficiency (folate, B12, B6). Hyperhomocysteinemia (HHcy) causes hypomethylation which is an important mechanism that links Hcy to dementia. Supplementation with vitamins B aims at reducing the risk of neurodegenerative diseases. Current evidence suggests that Hcy-lowering treatment has a positive effect for the secondary and primary prevention of stroke. HHcy is very common in patients with Parkinson disease particularly those who receive L-dopa treatment. Furthermore, a positive association has been reported between HHcy and multiple sclerosis. Moreover, HHcy and vitamin B deficiency are reported to have a causal role in depression, and epilepsy. In addition several anti-epileptic drugs cause secondary HHcy. Therefore, sufficient intakes of the vitamins are recommended for patients who have already developed neuropsychiatric diseases. Vitamin B deficiency should be suspected in children with development disorders, failure to thrive and unexplained neurological manifestations. Elderly people are also an important at-risk group where vitamin B deficiency and HHcy have been linked to neurodegenerative diseases. Treatment with folate, B12, and B6 can improve cerebral function. Preventive vitamin B supplementation and sufficient intake seem very important for secondary and primary prevention of neuropsychiatric disorders, especially in subjects with a low intake or status of the vitamins.

Authors+Show Affiliations

Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum des Saarlandes, Kirrberger Strasse, Gebaude 57, 66421 Homburg. prof.wolfgang.herrmann@uni-klinikum-saarland.deNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

17729191

Citation

Herrmann, W, et al. "[Review of the Role of Hyperhomocysteinemia and B-vitamin Deficiency in Neurological and Psychiatric Disorders--current Evidence and Preliminary Recommendations]." Fortschritte Der Neurologie-Psychiatrie, vol. 75, no. 9, 2007, pp. 515-27.
Herrmann W, Lorenzl S, Obeid R. [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations]. Fortschr Neurol Psychiatr. 2007;75(9):515-27.
Herrmann, W., Lorenzl, S., & Obeid, R. (2007). [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations]. Fortschritte Der Neurologie-Psychiatrie, 75(9), pp. 515-27.
Herrmann W, Lorenzl S, Obeid R. [Review of the Role of Hyperhomocysteinemia and B-vitamin Deficiency in Neurological and Psychiatric Disorders--current Evidence and Preliminary Recommendations]. Fortschr Neurol Psychiatr. 2007;75(9):515-27. PubMed PMID: 17729191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations]. AU - Herrmann,W, AU - Lorenzl,S, AU - Obeid,R, PY - 2007/8/31/pubmed PY - 2007/10/30/medline PY - 2007/8/31/entrez SP - 515 EP - 27 JF - Fortschritte der Neurologie-Psychiatrie JO - Fortschr Neurol Psychiatr VL - 75 IS - 9 N2 - Elevated concentration of total homocysteine (Hcy) in plasma (> 12 micromol/l) is a risk factor for several diseases of the central nervous system. Epidemiological studies have shown a dose-dependent relationship between concentrations of Hcy and the risk for neurodegenerative diseases. Hcy is a marker for B-vitamin deficiency (folate, B12, B6). Hyperhomocysteinemia (HHcy) causes hypomethylation which is an important mechanism that links Hcy to dementia. Supplementation with vitamins B aims at reducing the risk of neurodegenerative diseases. Current evidence suggests that Hcy-lowering treatment has a positive effect for the secondary and primary prevention of stroke. HHcy is very common in patients with Parkinson disease particularly those who receive L-dopa treatment. Furthermore, a positive association has been reported between HHcy and multiple sclerosis. Moreover, HHcy and vitamin B deficiency are reported to have a causal role in depression, and epilepsy. In addition several anti-epileptic drugs cause secondary HHcy. Therefore, sufficient intakes of the vitamins are recommended for patients who have already developed neuropsychiatric diseases. Vitamin B deficiency should be suspected in children with development disorders, failure to thrive and unexplained neurological manifestations. Elderly people are also an important at-risk group where vitamin B deficiency and HHcy have been linked to neurodegenerative diseases. Treatment with folate, B12, and B6 can improve cerebral function. Preventive vitamin B supplementation and sufficient intake seem very important for secondary and primary prevention of neuropsychiatric disorders, especially in subjects with a low intake or status of the vitamins. SN - 0720-4299 UR - https://www.unboundmedicine.com/medline/citation/17729191/[Review_of_the_role_of_hyperhomocysteinemia_and_B_vitamin_deficiency_in_neurological_and_psychiatric_disorders__current_evidence_and_preliminary_recommendations]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-980112 DB - PRIME DP - Unbound Medicine ER -